Triterpene derivatives that block entry of human immunodeficiency virus type 1 into cells.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 8170948.
- Also identified by PMC identifier 43620.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A series of triterpene compounds characterized by a stringent structure-activity relationship were identified as potent and selective inhibitors of human immunodeficiency virus type 1 (HIV-1) replication. Currently studied botulinic derivatives have 50% inhibitory concentrations (IC50) against HIV-1 strain IIIB/LAI in the 10 nM range in several cellular infection assays but are inactive against HIV-2. These compounds did not significantly inhibit the in vitro activities of several purified HIV-1 enzymes. Rather, they appeared to block virus infection at a postbinding, envelope-dependent step involved in the fusion of the virus to the cell membrane.
Medical subject headings
- Antiviral Agents
- HIV Infections
- HIV-1
- Triterpenes